|Acquired by||EUSA Pharma|
Cytogen Corporation, a biopharmaceutical company, builds, develops, and commercializes a portfolio of specialty pharmaceutical products for the treatment of cancer. It markets QUADRAMET (samarium Sm-153 lexidronam injection), PROSTASCINT (capromab pendetide), and SOLTAMOX (tamoxifen citrate) to the United States oncology market. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a prostate-specific membrane antigen (PSMA)-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. The company also offers CAPHOSOL, an advanced electrolyte solution for the treatment of oral mucositis and dry mouth. CAPHOSOL is approved in the U.S. as a prescription medical device. It is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. The company was founded in 1980. It was formerly known as Hybridex, Inc. and changed its name to Cytogen Corporation in the same year. Cytogen Corporation is based in Princeton, New Jersey. As of May 8, 2008, Cytogen Corporation operates as a subsidiary of EUSA Pharma Inc.